Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$16.58 USD

16.58
8,484,226

+0.08 (0.49%)

Updated Aug 9, 2024 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Envista (NVST) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Envista (NVST) Beats Q2 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 4.88% and 1.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

Envista (NVST) Q1 Earnings and Revenues Miss Estimates

Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Surpasses Q4 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Q3 Earnings Match Estimates

Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Earnings Expected to Grow: Should You Buy?

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Q2 Earnings Top Estimates

Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Q1 Earnings and Revenues Top Estimates

Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

Is Indivior PLC (INVVY) Outperforming Other Medical Stocks This Year?

Here is how Indivior PLC (INVVY) and Envista (NVST) have performed compared to their sector so far this year.

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow

Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.

Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat

Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.

Envista (NVST) Beats Q4 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?